These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 27649063)

  • 1. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.
    Racosta JM; Sposato LA; Kimpinski K
    Muscle Nerve; 2017 Jun; 55(6):802-809. PubMed ID: 27649063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.
    Boërio D; Créange A; Hogrel JY; Guéguen A; Bertrand D; Lefaucheur JP
    J Neurol Sci; 2010 May; 292(1-2):63-71. PubMed ID: 20219211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulins in patients with clinically suspected chronic immune-mediated neuropathy.
    Lucke IM; Adrichem ME; Wieske L; van der Kooi AJ; Verhamme C; van Schaik IN; Eftimov F
    J Neurol Sci; 2019 Feb; 397():141-145. PubMed ID: 30623818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin for treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in France: are daily practices in accordance with guidelines?
    Rosier C; Graveline N; Lacour A; Antoine JC; Camdessanché JP
    Eur J Neurol; 2019 Apr; 26(4):575-580. PubMed ID: 30326184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy.
    Hughes RA
    Rev Neurol (Paris); 2002 Dec; 158(12 Pt 2):S32-6. PubMed ID: 12690659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of different brands of intravenous immunoglobulin in the maintenance treatment of chronic immune-mediated neuropathies.
    Gallia F; Balducci C; Nobile-Orazio E
    J Peripher Nerv Syst; 2016 Jun; 21(2):82-4. PubMed ID: 26817673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
    Markvardsen LH; Christiansen I; Jakobsen J
    Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatments of chronic immune-mediated demyelinating polyneuropathies.
    Brannagan TH
    Muscle Nerve; 2009 May; 39(5):563-78. PubMed ID: 19301378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
    Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
    Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy.
    Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R
    Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on therapy of chronic immune-mediated neuropathies.
    Briani C; Cocito D; Campagnolo M; Doneddu PE; Nobile-Orazio E
    Neurol Sci; 2022 Dec; 43(Suppl 2):605-614. PubMed ID: 33452933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study.
    Cocito D; Merola A; Peci E; Mazzeo A; Fazio R; Francia A; Valentino P; Liguori R; Filosto M; Siciliano G; Clerici AM; Lelli S; Marfia GA; Antonini G; Cecconi I; Nobile-Orazio E; Lopiano L;
    J Neurol; 2014 Nov; 261(11):2159-64. PubMed ID: 25149866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and patient satisfaction in the use of subcutaneous immunoglobulin immunotherapy for the treatment of auto-immune neuromuscular diseases.
    Sala TP; Crave JC; Duracinsky M; Lepira Bompeka F; Tadmouri A; Chassany O; Cherin P
    Autoimmun Rev; 2018 Sep; 17(9):873-881. PubMed ID: 30005853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dramatic clinical response to ultra-high dose IVIg in otherwise treatment resistant inflammatory neuropathies.
    Kapoor M; Reilly MM; Manji H; Lunn MP; Aisling S ; Carr
    Int J Neurosci; 2022 Apr; 132(4):352-361. PubMed ID: 32842835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients.
    Debs R; Reach P; Cret C; Demeret S; Saheb S; Maisonobe T; Viala K
    Int J Neurosci; 2017 Oct; 127(10):864-872. PubMed ID: 27918219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies.
    Dalakas MC
    J Peripher Nerv Syst; 2012 May; 17 Suppl 2():34-9. PubMed ID: 22548621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic costs and quality of life in chronic inflammatory neuropathies in southeast England.
    Mahdi-Rogers M; McCrone P; Hughes RA
    Eur J Neurol; 2014; 21(1):34-9. PubMed ID: 23930744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic immune-mediated neuropathies: chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and the Lewis-Sumner syndrome.
    Sederholm BH
    Semin Neurol; 2010 Sep; 30(4):443-56. PubMed ID: 20941678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous vs. intravenous immunoglobulin in CIDP: pharmacokinetic and clinical response.
    Cocito D; Romagnolo A; Peci E; Rosso M; Lopiano L; Milla P; Merola A
    J Peripher Nerv Syst; 2016 Jun; 21(2):114-6. PubMed ID: 27251938
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 29.